Table 4.
Results of univariate and multivariate analyses for CSS, OS and PFS after propensity score matching
| Characteristics | CSS | OS | PFS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||
| P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | |
| Aged >65 years | 0.501 | 1.144 (0.773–1.692) | 0.041 | 1.427 (1.015–2.006) | 0.016 | 1.615 (1.091–2.389) | 0.615 | 0.932 (0.708–1.227) | ||||
| Gender (male) | 0.001 | 1.950 (1.332–2.885) | 0.002 | 1.992 (1.300–3.053) | 0.014 | 1.482 (1.084–2.026) | 0.063 | 1.396 (0.982–1.985) | 0.015 | 1.394 (1.067–1.821) | 0.004 | 1.560 (1.149–2.119) |
| BMI | 0.033 | 0.942 (0.891–0.995) | 0.086 | 0.961 (0.919–1.006) | 0.145 | 0.972 (0.936–1.010) | ||||||
| Diabetes | 0.561 | 0.858 (0.512–1.438) | 0.624 | 0.899 (0.586–1.378) | 0.992 | 0.998 (0.701–1.422) | ||||||
| Hypertension | 0.871 | 1.032 (0.706–1.508) | 0.146 | 1.262 (0.922–1.726) | 0.74 | 0.955 (0.725–1.257) | ||||||
| Coronary disease | 0.975 | 0.991 (0.556–1.767) | 0.560 | 1.147 (0.724–1.815) | 0.829 | 1.046 (0.694–1.576) | ||||||
| Alcohol | 0.780 | 1.086 (0.609–1.937) | 0.640 | 1.121 (0.694–1.811) | 0.406 | 0.826 (0.526–1.296) | 0.070 | 0.624 (0.374–1.040) | ||||
| Tobacco | 0.346 | 1.252 (0.785–1.996) | 0.447 | 1.167 (0.784–1.737) | 0.585 | 0.903 (0.626–1.303) | ||||||
| Hydronephrosis | 0.353 | 1.194 (0.822–1.734) | 0.412 | 1.140 (0.834–1.559) | 0.020 | 1.600 (1.077–2.377) | 0.195 | 1.193 (0.913–1.559) | ||||
| AST/ALT ≥1.23 | <0.001 | 2.313 (1.551–3.450) | <0.001 | 2.977 (1.904–4.653) | <0.001 | 1.942 (1.402–2.689) | <0.001 | 2.049 (1.426–2.945) | <0.001 | 1.684 (1.28–2.216) | <0.001 | 1.834 (1.348–2.496) |
| Tumor location (pelvis) |
0.088 | 1.389 (0.953–2.024) | 0.004 | 1.600 (1.161–2.205) | 0.003 | 1.847 (1.238–2.755) | 0.862 | 0.977 (0.748–1.276) | ||||
| T Stage (≥3) | <0.001 | 3.393 (2.341–4.919) | 0.002 | 2.006 (1.303–3.089) | <0.001 | 2.558 (1.869–3.501) | 0.006 | 1.728 (1.168–2.558) | 0.015 | 1.421 (1.072–1.884) | ||
| Tumor size (>5 cm) | <0.001 | 3.228 (2.141–4.867) | 0.001 | 2.141 (1.353–3.387) | <0.001 | 2.675 (1.849–3.871) | <0.001 | 2.592 (1.669–4.025) | 0.003 | 1.682 (1.199–2.360) | 0.009 | 1.655 (1.133–2.418) |
| N Stage (≥1) | <0.001 | 3.817 (2.352–6.193) | <0.001 | 2.785 (1.631–4.757) | <0.001 | 2.753 (1.739–4.359) | 0.012 | 1.944 (1.159–3.261) | 0.098 | 1.475 (0.931–2.337) | ||
| Cellular grade (≥3) | <0.001 | 2.376 (1.628–3.468) | <0.001 | 1.949 (1.426–2.665) | 0.068 | 1.440 (0.973–2.130) | 0.121 | 1.236 (0.946–1.616) | ||||
| Lymphatic microvascular invasion | 0.077 | 1.916 (0.933–3.936) | 0.403 | 1.355 (0.665–2.761) | 0.511 | 1.226 (0.668–2.250) | ||||||
| Tumor necrosis | 0.156 | 1.440 (0.870–2.386) | 0.150 | 1.376 (0.891–2.125) | 0.075 | 0.591 (0.332–1.053) | 0.352 | 1.204 (0.814–1.782) | ||||
| Tumor hemorrhage | 0.090 | 1.939 (0.902–4.169) | 0.023 | 2.491 (1.137–5.459) | 0.057 | 1.862 (0.981–3.534) | 0.004 | 2.920 (1.417–6.017) | 0.444 | 1.298 (0.666–2.530) | ||
| Tumor architecture (sessile) | <0.001 | 2.268 (1.524–3.375) | <0.001 | 1.935 (1.369–2.735) | 0.112 | 1.298 (0.941–1.790) | ||||||
| Squamous metaplasia | 0.012 | 2.008 (1.164–3.466) | 0.011 | 1.873 (1.157–3.030) | 0.497 | 1.173 (0.740–1.860) | ||||||
| Sarcomatoid differentiation | 0.001 | 2.954 (1.541–5.661) | <0.001 | 2.984 (1.722–5.170) | 0.332 | 1.351 (0.736–2.478) | ||||||
| Glandular differentiation | 0.004 | 2.759 (1.393–5.466) | 0.031 | 2.357 (1.081–5.141) | 0.001 | 2.852 (1.579–5.153) | 0.006 | 2.660 (1.322–5.354) | 0.084 | 1.673 (0.933–3.000) | ||
| Laparoscopy | 0.054 | 0.628 (0.391–1.008) | 0.405 | 0.852 (0.584–1.243) | 0.359 | 0.858 (0.619–1.190) | ||||||
Abbreviations: CSS, cancer-specific survival; OS, overall survival; PFS, progression-free survival; PSM, propensity score matching.